Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab

Pedro Miguel Garrido¹, Maria Inês Alexandre², Ana Rita Travassos¹, Paulo Filipe^{1

3

4}

Affiliations

¹ Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), Lisbon, Portugal.
² Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), Lisbon, Portugal.
³ Dermatology Universitary Clinic, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
⁴ Dermatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

Pedro Miguel Garrido et al. Dermatol Ther. 2020 Nov.

. 2020 Nov;33(6):e14160.

doi: 10.1111/dth.14160. Epub 2020 Sep 6.

Pedro Miguel Garrido¹, Maria Inês Alexandre², Ana Rita Travassos¹, Paulo Filipe^{1

3

4}

¹ Dermatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), Lisbon, Portugal.
² Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (CHULN), Lisbon, Portugal.
³ Dermatology Universitary Clinic, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
⁴ Dermatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.

No abstract available

References

1. Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867-877.
1. Van Beek N, Schulze FS, Zillikens D, Schmidt E. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol. 2016;12(3):267-277.
1. Garrido PM, Queirós CS, Travassos AR, Borges-Costa J, Filipe P. Emerging treatments for bullous pemphigoid. J Dermatolog Treat. 2020;1-31.
1. Fairley JA, Baum CL, Brandt DS, Messingham KAN. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123(3):704-705.
1. Hashimoto T, Ohzono A, Teye K, et al. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol. 2017;177(1):141-151.